Identification and characterization of a novel LRRK2 kinase inhibitor: ODS2005294

Ipsen Innovation ; Oncodesign SA.


Ex-vivo inhibition of LRRK2 phosphorylation by a new kinase inhibitor in peripheral blood cells of subjects with and without G2019S LRRK2 mutation

Ipsen ; Inserm UMRS ; CHU Pitié-Salpêtrière ; Service de Neurologie Hop. de Hautepierre Strasbourg ; Fédération de Médecine Translationnelle, Strasbourg ; Inserm U.836-UJF-CEA-CHU, Grenoble ; Inserm Nantes ; Service de Neurologie, CHU de Lyon ; Inserm Toulouse; Inserm Paris


By closing this message, you consent to our cookies on this device in accordance with our cookie policy unless you have disabled them.